Full-Time

Asset & Wealth Management Associate

Life Sciences

Goldman Sachs

Goldman Sachs

10,001+ employees

Global investment banking, securities, asset management

Compensation Overview

$150k - $225k/yr

+ Bonus (discretionary)

Company Historically Provides H1B Sponsorship

San Francisco, CA, USA

In Person

Category
Finance & Banking (1)
Required Skills
Financial Modeling
Requirements
  • Undergraduate degree in life sciences and/or relevant graduate degree (MD, PhD, MS, MBA)
  • High degree of fluency in scientific and medical related topics, including human biology, physiology, and disease pathology with an ability to come up to speed quickly across therapeutic areas
  • Familiarity with stages of drug development and ability to evaluate preclinical and clinical data sets
  • Familiarity and experience with financial modeling including discounted cash flow and three-statement modeling
  • Strong analytical ability, creativity, thoughtful business judgment, and professional maturity
  • High energy level, strong communication skills, intellectual curiosity, and a passion for investing
  • Outstanding organizational and communication skills, ability to multi-task, and manage various deadlines
  • Desire to collaborate with colleagues throughout the firm globally
  • Ability to work seamlessly with senior and junior investment team to drive investments forward
Responsibilities
  • Perform scientific and business due diligence on potential investment opportunities including primary diligence (e.g., management team presentations, data room access) and secondary diligence (e.g. academic literature, key opinion leaders, industry experts)
  • Prepare business and financial analyses including company projections and valuation analyses
  • Help prepare and revise investment related documentation including memos, term sheets, purchase agreements, and other related items
  • Create scientific diligence memos for various therapeutic areas of focus
  • Build and maintain financial models and understand industry trends as well as competitive dynamics for portfolio companies and prospective investments
  • Produce company-specific and general biotech reports and presentations around new and existing drugs in development as well as emerging opportunity areas
  • Present investment theses to key stakeholders, including our advisory board and Investment Committee
  • Manage key aspects of the investment process, including internal diligence workstreams
  • Maintain internal databases relevant to the team
  • Work across multiple projects simultaneously with a high degree of communication and coordination
  • Collaborate with professionals across the team and firm and positively contribute to the overall culture
Desired Qualifications
  • Prior work experience in life sciences related field preferred (e.g. consulting, banking, investing or operating company)

Goldman Sachs delivers financial services across investment banking, securities, and asset management to corporations, governments, financial institutions, and high-net-worth individuals. Its offerings include advising on mergers and acquisitions, underwriting and distributing new securities, and managing client assets, with revenue from advisory and underwriting fees, trading commissions, and asset-management fees. The firm differentiates itself through a global reach, an integrated capital-markets platform, and deep client relationships that enable end-to-end financial solutions. Its goal is to help clients raise capital, grow their businesses, manage risk, and generate returns, while pursuing social responsibility initiatives that support small businesses and promote racial equity.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1869

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 net earnings surged 19% year-over-year to $5.6 billion.
  • Raised price targets on Broadcom, Fluence Energy, Nvidia amid AI infrastructure boom.
  • Record backlog and hyperscaler partnerships drive data center and semiconductor advisory fees.

What critics are saying

  • Operating expenses grew 14% matching revenue growth, compressing margins unsustainably.
  • Operating cash flow collapsed to negative $31.9 billion in Q1 2026.
  • Total liabilities exploded 18.1% year-over-year to $1.94 trillion, amplifying systemic risk.

What makes Goldman Sachs unique

  • Manages $3 trillion in assets under supervision with top-tier alternatives business.
  • Underwrites major medtech IPOs like Mobia Medical's $150M stroke recovery device offering.
  • Expanded management committee to 47 members with AI and risk strategy leaders.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Goldman Sachs who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

Professional Development Budget

Company News

Yahoo Finance
Apr 14th, 2026
Big banks profit from AI data center borrowing and Iran war volatility

Wall Street's major banks are reporting strong earnings, with JPMorgan and Goldman Sachs benefitting from AI infrastructure buildout and geopolitical volatility. JPMorgan posted net income of $16.5 billion, up 13% year over year, whilst Goldman saw investment banking fees jump 48%. The AI boom is driving unprecedented corporate borrowing, with banks profiting from debt underwriting, bond trading and advisory services. Goldman led Oracle's $25 billion bond offering in February, one of the largest corporate sales recently. JPMorgan CEO Jamie Dimon cited "AI-driven capital investment" as a key macroeconomic driver. Meanwhile, war-related volatility is boosting trading desks. JPMorgan's fixed income trading rose 21%, driven by activity in commodities, credit and currencies. Goldman's equities division surged 27%, reflecting increased client hedging activity amid geopolitical uncertainty.

Yahoo Finance
Apr 14th, 2026
Goldman Sachs cuts Amazon price target to $275 amid $200B AI spending concerns

Goldman Sachs has lowered its price target on Amazon to $275 from $280 whilst maintaining a Buy rating ahead of the company's earnings report on 30 April 2026. The revised target still implies upside from the current share price of around $240. Analyst Eric Sheridan highlighted four key areas shaping Amazon's trajectory: AWS cloud revenue growth and AI investment returns, rising energy prices affecting margins, the commercialisation timeline for Amazon Leo, and the fast-growing advertising platform. Amazon's AI push through AWS has reached an annualised revenue run rate exceeding $15 billion, whilst its chip business surpassed $20 billion in revenue with triple-digit growth. However, capital expenditures could approach $200 billion in fiscal 2026, pressuring free cash flow despite strong overall performance showing net sales of $716.9 billion and operating income of $80 billion for the full year.

Tech in Asia
Apr 14th, 2026
Goldman Sachs deploys Anthropic's Claude Mythos AI to find cyber vulnerabilities after US urging

Goldman Sachs is strengthening its cyber defences using Anthropic's Claude Mythos Preview AI model, according to CEO David Solomon. The bank is collaborating with Anthropic and security vendors to accelerate investment in its security infrastructure. Treasury Secretary Scott Bessent and Federal Reserve Chair Jerome Powell convened an urgent meeting with Wall Street leaders in Washington, urging banks to test the model against their systems. Mythos is designed to identify complex exploit chains—linked software vulnerabilities used in sophisticated cyberattacks that security researchers often miss. The model has discovered thousands of bugs, including one in OpenBSD that remained undetected for 27 years. US officials are pushing critical industries towards machine-scale cyber defence, though the approach has sparked international friction with European regulators and internal US government disagreements.

American Banker
Apr 14th, 2026
Goldman Sachs raises $6.5B in bond sale amid market volatility

Goldman Sachs raised $6.5 billion from a US investment-grade bond sale, continuing a borrowing spree that included a record $16 billion offering earlier this year. The deal tested investor appetite after the bank reported weaker-than-expected bond-trading revenue in its first quarter. Pricing tightened by approximately 0.25 percentage points across two fixed-rate tranches, with the longest maturity due in 2034 priced at a one percentage point spread. The offering also included a floating-rate note, with proceeds earmarked for general corporate purposes. Goldman led first-quarter debt issuance among Wall Street banks. However, analysts note that increased market volatility from AI disruption concerns and Middle East tensions has made borrowing conditions more challenging, with banks potentially front-loading 2026 issuance before costs rose.

Yahoo Finance
Apr 13th, 2026
Goldman Sachs falls 4.7% despite earnings beat on rising credit provisions and declining backlog

Goldman Sachs shares fell as much as 4.7% on Monday before recovering to close down 1.9%, despite reporting earnings that beat expectations. The investment bank posted revenue growth of 14.4% to $17.23 billion and earnings per share up 24.3% to $17.55, beating forecasts by $1.16. However, several factors concerned investors. Goldman's investment banking fee backlog declined slightly, potentially signalling future deceleration. Provisions for credit losses exceeded expectations due to macroeconomic uncertainty and portfolio growth, compressing net interest margins. CEO David Solomon also indicated the bank would continue investing in private credit despite recent market volatility in that sector. The pullback appears to reflect profit-taking after an 80% share price gain over the past year, rather than fundamental concerns.